Department of Ophthalmology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, China.
Clin Exp Ophthalmol. 2012 Dec;40(9):888-94. doi: 10.1111/j.1442-9071.2012.02815.x. Epub 2012 Jul 2.
To assess intravitreal injection dose and safety of recombinant adeno-associated virus-mediated gene delivery of human NADH dehydrogenase subunit 4 (ND4) in rabbit eyes.
An open reading frame for human ND4 or adeno-associated virus-green fluorescent protein were fused to the mitochondrial targeting sequence and packed into separate adeno-associated virus capsids. Rabbits of three treatment groups were administered 0.1 mL adeno-associated virus-ND4, 0.1 mL adeno-associated virus-green fluorescent protein or 0.1 mL vehicle via intravitreal injection, respectively. The safety of recombinant adenoassociated virus-mediated gene delivery of human ND4 in rabbit eyes was assessed with a slit-lamp microscope and direct ophthalmoscope, measurements of intraocular pressure and flash visual evoked potential, and optical coherence tomography. The mRNA and protein expressions of human ND4 in the retina of rabbits were determined with real-time polymer chain reaction (PCR), immunofluorescence and Western blot.
No complications occurred in any of the three treatment groups after the intravitreal injection. At 1-month post-injection, no significant difference in the mean thickness of retinal nerve fibre layer was found among the three groups. Results of the visual evoked potential test showed that there was no difference in the latency of the visual P100 wave among the three groups. Real-time PCR, immunofluorescence and Western blot analyses verified the expressions of ND4 and green fluorescent protein in the retinal nerve fibre layer.
Intravitreal injection of adeno-associated virus-ND4 expression vectors was effectively and safely performed in our study. The data on the dose and method of intravitreal injection from our study will provide a valuable reference for clinical intravitreal injection of adeno-associated virus-ND4 for the treatment of Leber's hereditary optic neuropathy.
评估重组腺相关病毒介导的人 NADH 脱氢酶亚单位 4(ND4)基因在兔眼内的玻璃体内注射剂量和安全性。
人 ND4 的开放阅读框或腺相关病毒-绿色荧光蛋白与线粒体靶向序列融合,并分别包装到单独的腺相关病毒衣壳中。三组治疗组的兔子分别通过玻璃体内注射接受 0.1ml 腺相关病毒-ND4、0.1ml 腺相关病毒-绿色荧光蛋白或 0.1ml 载体。通过裂隙灯显微镜和直接检眼镜、眼内压和闪光视觉诱发电位以及光学相干断层扫描评估重组腺相关病毒介导的人 ND4 在兔眼内的基因传递的安全性。用实时聚合酶链反应(PCR)、免疫荧光和 Western blot 测定兔视网膜中人 ND4 的 mRNA 和蛋白表达。
玻璃体内注射后三组均未发生任何并发症。注射后 1 个月,三组视网膜神经纤维层平均厚度无显著差异。视觉诱发电位测试结果表明,三组的视觉 P100 波潜伏期无差异。实时 PCR、免疫荧光和 Western blot 分析证实了 ND4 和绿色荧光蛋白在视网膜神经纤维层中的表达。
在本研究中,成功有效地进行了玻璃体内注射腺相关病毒-ND4 表达载体。本研究中关于玻璃体内注射剂量和方法的资料将为临床应用腺相关病毒-ND4 治疗莱伯遗传性视神经病变的玻璃体内注射提供有价值的参考。